This presentation is about colon targrte drug delivery with morden technologies and new approaches

1. Seminar on Colonspecific Drug Delivery Prepared By:- Ashish Savaliya, M.Pharm-II P’Ceutics, NIMS University,Jaipur

3. Disadvantages Applications Conclusion References 25-Nov-10 NIMS University,Jaipur 3

5. To delay delivery to the colon to achieve high local concentrations in the treatment of diseases of the distal gut,

6. To delay delivery to a time appropriate to treat acute phases of disease (chronotherapy),

8. 25-Nov-10 NIMS University,Jaipur 8 Ulcerative colitis

9. 25-Nov-10 NIMS University,Jaipur 9 Crohn’s disease

14. 25-Nov-10 NIMS University,Jaipur 15

15. 25-Nov-10 NIMS University,Jaipur 16

19. Azoreductase

20. N-oxide reductase

21. Sulphoxidereductase

23. Amidases

24. Glycosidases

25. Glucuronidase

26. Sulfatase

27. Azoreductases, which reduces azo-bonds selectively and

29. Releases the drug after a predetermined lag time.

30. The lag time usually starts after gastric emptying because most of the time-controlled formulations are enteric coated.

31. The enteric polymer coat prevents drug release in the stomach.

32. Drug release from these systems is not pH dependent.

38. Pellets containing the drug (prednisolone metasulphobenzoate) with a coating of ethylcelluloseand a specific form of amylose (derived from starch).

41. Is device of ‘Philips research’ available in market from 2008

42. The ‘iPill’ is a capsule and it has been designed to be swallowed and to pass through the digestive track naturally. It can be electronically programmed to control the delivery of medicine according to a pre-defined drug release profile.

45. The Enterioncapsule has recently been developed by Phaeton Research, Nottingham, UK, for targeted delivery of a wide range of different drug formulations into any region of the colon.

46. The capsule can be loaded with either a liquid formulation (eg. solution, suspension) or a particulate formulation (eg. powder, pellets, minitablets, etc.)

49. This magnetic field induce power in a tuned coil antenna, embedded in capsule wall. This power is fed to a tiny heater resistor located in capsule.

50. This heater resistor increases temperature & releases the spring & drives the piston.

55. Patient compliance and treatment efficacy

56. Useful in treatment of ulcerative colitis, crohn's disease, irritable bowel syndrome and carcinomas

57. Low dose is required ,so less side effect

58. Used for local and systemic action

60. There is less fluid in colon than in small intestine and hence, dissolution is a problem for water soluble drugs.

61. Binding of drug to dietary residues, intestinal secretions etc., reduce concentration of free drugs.

62. Some micro flora may degrade the drug.

63. Small luminal surface area and relative tightness of tight Junctions in colon, delay the systemic absorption.

66. Colonic drug delivery are one of the major challenges.

67. Management of Local pathologies requires efforts in decreasing or eliminating side effects .

68. Conventional dosage forms need to be drastically improved in their design.

69. Drug delivery to specific site i.e. colon is a potential alternativefor improvement in therapy.

70. Colon provides favorable factors and conditions for designing of delivery systems.

72. Modified-Release Drug Delivery Technology by Michael J. Rathbone, Jonathan Hadgraft.

73. Colonic Drug Delivery by Clive G. Wilson

74. Time Dependent System For Colonic Drug Delivery by GourMukherji

75. Pulsincap System For Colonic Drug Delivery by HowardN.E.Stevens

76. The Enterion Capsule by David V. Prior, Alyson L. Connor, and Ian R. Wilding*